Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis
Background and Purpose The clinical correlation of gadolinium‐based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self‐reported disability and performance measures. Methods A cohort of M...
Gespeichert in:
Veröffentlicht in: | Journal of neuroimaging 2023-01, Vol.33 (1), p.85-93 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 93 |
---|---|
container_issue | 1 |
container_start_page | 85 |
container_title | Journal of neuroimaging |
container_volume | 33 |
creator | Nakamura, Kunio McGinley, Marisa P. Jones, Stephen E. Lowe, Mark J. Cohen, Jeffrey A. Ruggieri, Paul M. Ontaneda, Daniel |
description | Background and Purpose
The clinical correlation of gadolinium‐based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self‐reported disability and performance measures.
Methods
A cohort of MS patients was analyzed in this retrospective observational study. The main outcome was the association between the cumulative number of GBCA exposures (linear or macrocyclic GBCA), Patient‐Determined Disease Steps (PDDS), and measures of physical and cognitive performance (walking speed test, manual dexterity test [MDT], and processing speed test [PST]). The analysis was performed first cross‐sectionally and then longitudinally.
Results
The cross‐sectional data included 1059 MS patients with a mean age of 44.0 years (standard deviation = 11.2). While the contrast ratio in globus pallidus weakly correlated with PDDS, MDT, and PST in a univariate correlational analysis (coefficients, 95% confidence interval [CI] = 0.11 [0.04, 0.18], 0.15 [0.08, 0.21], and –0.16 [–0.10, –0.23], respectively), the associations disappeared after covariate adjustment. A significant association was found between number of linear GBCA administrations and PDDS (coefficient [CI] = –0.131 [–0.196, –0.067]), and MDT associated with macrocyclic GBCA administrations (–0.385 [–0.616, –0.154]), but their signs indicated better outcomes in patients with greater GBCA exposures. The longitudinal data showed no significant detrimental effect of macrocyclic GBCA exposures.
Conclusion
No detrimental effects were observed between GBCA exposure and self‐reported disability and standardized objective measures of physical and cognitive performance. While several weak associations were found, they indicated benefit on these measures. |
doi_str_mv | 10.1111/jon.13057 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9847209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2720430212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4437-b9b0b4cdf42e840f537b113d439d6d5cebd0f757d9e5a19df0b012c763d2b65e3</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi0EoqWw4AWQJTawSOt7kg0SqqCAKrqBteXL5NRHjh3ipHB2PALPyJPg9pQKkPDGtvz508z8CD2l5JjWdbLN6ZhyItt76JBKyRolVX-_nomkDWOdOECPStkSwqhg_CE64Ip2VCl1iDZnxucYUljHn99_WFPAY5fTMpuyYLOBtGD4NuWyzlCwSR5Pl7sSnIk3F5c3KSzhCrAPxdgQw7LDIeFxjUuYIuDiIsy5hPIYPRhMLPDkdj9Cn9---XT6rjm_OHt_-vq8cULwtrG9JVY4PwgGnSCD5K2llHvBe6-8dGA9GVrZ-h6kob0fiCWUuVZxz6ySwI_Qq713Wu0I3sF1K1FPcxjNvNPZBP33SwqXepOvdN-JlpG-Cl7cCub8ZYWy6DEUBzGaBHktmlVK8DpJVtHn_6DbvM6ptlcpVXW8E7JSL_eUq4MoMwx3xVCir-Orv5K-ia-yz_6s_o78nVcFTvbA1xBh93-T_nDxca_8BWd8qCs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2764723845</pqid></control><display><type>article</type><title>Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Nakamura, Kunio ; McGinley, Marisa P. ; Jones, Stephen E. ; Lowe, Mark J. ; Cohen, Jeffrey A. ; Ruggieri, Paul M. ; Ontaneda, Daniel</creator><creatorcontrib>Nakamura, Kunio ; McGinley, Marisa P. ; Jones, Stephen E. ; Lowe, Mark J. ; Cohen, Jeffrey A. ; Ruggieri, Paul M. ; Ontaneda, Daniel</creatorcontrib><description>Background and Purpose
The clinical correlation of gadolinium‐based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self‐reported disability and performance measures.
Methods
A cohort of MS patients was analyzed in this retrospective observational study. The main outcome was the association between the cumulative number of GBCA exposures (linear or macrocyclic GBCA), Patient‐Determined Disease Steps (PDDS), and measures of physical and cognitive performance (walking speed test, manual dexterity test [MDT], and processing speed test [PST]). The analysis was performed first cross‐sectionally and then longitudinally.
Results
The cross‐sectional data included 1059 MS patients with a mean age of 44.0 years (standard deviation = 11.2). While the contrast ratio in globus pallidus weakly correlated with PDDS, MDT, and PST in a univariate correlational analysis (coefficients, 95% confidence interval [CI] = 0.11 [0.04, 0.18], 0.15 [0.08, 0.21], and –0.16 [–0.10, –0.23], respectively), the associations disappeared after covariate adjustment. A significant association was found between number of linear GBCA administrations and PDDS (coefficient [CI] = –0.131 [–0.196, –0.067]), and MDT associated with macrocyclic GBCA administrations (–0.385 [–0.616, –0.154]), but their signs indicated better outcomes in patients with greater GBCA exposures. The longitudinal data showed no significant detrimental effect of macrocyclic GBCA exposures.
Conclusion
No detrimental effects were observed between GBCA exposure and self‐reported disability and standardized objective measures of physical and cognitive performance. While several weak associations were found, they indicated benefit on these measures.</description><identifier>ISSN: 1051-2284</identifier><identifier>EISSN: 1552-6569</identifier><identifier>DOI: 10.1111/jon.13057</identifier><identifier>PMID: 36181666</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Clinical Investigative Study ; Cognitive ability ; Contrast agents ; Contrast media ; Contrast Media - adverse effects ; Cross-Sectional Studies ; Exposure ; Gadolinium ; Gadolinium - adverse effects ; Gadolinium DTPA ; gadolinium‐based contrast agent ; Globus pallidus ; Humans ; magnetic resonance imaging ; Magnetic Resonance Imaging - methods ; Manual dexterity ; Multiple sclerosis ; Multiple Sclerosis - diagnostic imaging ; Neuroimaging ; Organometallic Compounds ; Original Research ; Processing Speed ; Retrospective Studies</subject><ispartof>Journal of neuroimaging, 2023-01, Vol.33 (1), p.85-93</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.</rights><rights>2022 The Authors. Journal of Neuroimaging published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4437-b9b0b4cdf42e840f537b113d439d6d5cebd0f757d9e5a19df0b012c763d2b65e3</citedby><cites>FETCH-LOGICAL-c4437-b9b0b4cdf42e840f537b113d439d6d5cebd0f757d9e5a19df0b012c763d2b65e3</cites><orcidid>0000-0002-7833-8138</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjon.13057$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjon.13057$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36181666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Kunio</creatorcontrib><creatorcontrib>McGinley, Marisa P.</creatorcontrib><creatorcontrib>Jones, Stephen E.</creatorcontrib><creatorcontrib>Lowe, Mark J.</creatorcontrib><creatorcontrib>Cohen, Jeffrey A.</creatorcontrib><creatorcontrib>Ruggieri, Paul M.</creatorcontrib><creatorcontrib>Ontaneda, Daniel</creatorcontrib><title>Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis</title><title>Journal of neuroimaging</title><addtitle>J Neuroimaging</addtitle><description>Background and Purpose
The clinical correlation of gadolinium‐based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self‐reported disability and performance measures.
Methods
A cohort of MS patients was analyzed in this retrospective observational study. The main outcome was the association between the cumulative number of GBCA exposures (linear or macrocyclic GBCA), Patient‐Determined Disease Steps (PDDS), and measures of physical and cognitive performance (walking speed test, manual dexterity test [MDT], and processing speed test [PST]). The analysis was performed first cross‐sectionally and then longitudinally.
Results
The cross‐sectional data included 1059 MS patients with a mean age of 44.0 years (standard deviation = 11.2). While the contrast ratio in globus pallidus weakly correlated with PDDS, MDT, and PST in a univariate correlational analysis (coefficients, 95% confidence interval [CI] = 0.11 [0.04, 0.18], 0.15 [0.08, 0.21], and –0.16 [–0.10, –0.23], respectively), the associations disappeared after covariate adjustment. A significant association was found between number of linear GBCA administrations and PDDS (coefficient [CI] = –0.131 [–0.196, –0.067]), and MDT associated with macrocyclic GBCA administrations (–0.385 [–0.616, –0.154]), but their signs indicated better outcomes in patients with greater GBCA exposures. The longitudinal data showed no significant detrimental effect of macrocyclic GBCA exposures.
Conclusion
No detrimental effects were observed between GBCA exposure and self‐reported disability and standardized objective measures of physical and cognitive performance. While several weak associations were found, they indicated benefit on these measures.</description><subject>Adult</subject><subject>Clinical Investigative Study</subject><subject>Cognitive ability</subject><subject>Contrast agents</subject><subject>Contrast media</subject><subject>Contrast Media - adverse effects</subject><subject>Cross-Sectional Studies</subject><subject>Exposure</subject><subject>Gadolinium</subject><subject>Gadolinium - adverse effects</subject><subject>Gadolinium DTPA</subject><subject>gadolinium‐based contrast agent</subject><subject>Globus pallidus</subject><subject>Humans</subject><subject>magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Manual dexterity</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - diagnostic imaging</subject><subject>Neuroimaging</subject><subject>Organometallic Compounds</subject><subject>Original Research</subject><subject>Processing Speed</subject><subject>Retrospective Studies</subject><issn>1051-2284</issn><issn>1552-6569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctu1TAQhi0EoqWw4AWQJTawSOt7kg0SqqCAKrqBteXL5NRHjh3ipHB2PALPyJPg9pQKkPDGtvz508z8CD2l5JjWdbLN6ZhyItt76JBKyRolVX-_nomkDWOdOECPStkSwqhg_CE64Ip2VCl1iDZnxucYUljHn99_WFPAY5fTMpuyYLOBtGD4NuWyzlCwSR5Pl7sSnIk3F5c3KSzhCrAPxdgQw7LDIeFxjUuYIuDiIsy5hPIYPRhMLPDkdj9Cn9---XT6rjm_OHt_-vq8cULwtrG9JVY4PwgGnSCD5K2llHvBe6-8dGA9GVrZ-h6kob0fiCWUuVZxz6ySwI_Qq713Wu0I3sF1K1FPcxjNvNPZBP33SwqXepOvdN-JlpG-Cl7cCub8ZYWy6DEUBzGaBHktmlVK8DpJVtHn_6DbvM6ptlcpVXW8E7JSL_eUq4MoMwx3xVCir-Orv5K-ia-yz_6s_o78nVcFTvbA1xBh93-T_nDxca_8BWd8qCs</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Nakamura, Kunio</creator><creator>McGinley, Marisa P.</creator><creator>Jones, Stephen E.</creator><creator>Lowe, Mark J.</creator><creator>Cohen, Jeffrey A.</creator><creator>Ruggieri, Paul M.</creator><creator>Ontaneda, Daniel</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7833-8138</orcidid></search><sort><creationdate>202301</creationdate><title>Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis</title><author>Nakamura, Kunio ; McGinley, Marisa P. ; Jones, Stephen E. ; Lowe, Mark J. ; Cohen, Jeffrey A. ; Ruggieri, Paul M. ; Ontaneda, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4437-b9b0b4cdf42e840f537b113d439d6d5cebd0f757d9e5a19df0b012c763d2b65e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Clinical Investigative Study</topic><topic>Cognitive ability</topic><topic>Contrast agents</topic><topic>Contrast media</topic><topic>Contrast Media - adverse effects</topic><topic>Cross-Sectional Studies</topic><topic>Exposure</topic><topic>Gadolinium</topic><topic>Gadolinium - adverse effects</topic><topic>Gadolinium DTPA</topic><topic>gadolinium‐based contrast agent</topic><topic>Globus pallidus</topic><topic>Humans</topic><topic>magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Manual dexterity</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - diagnostic imaging</topic><topic>Neuroimaging</topic><topic>Organometallic Compounds</topic><topic>Original Research</topic><topic>Processing Speed</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Kunio</creatorcontrib><creatorcontrib>McGinley, Marisa P.</creatorcontrib><creatorcontrib>Jones, Stephen E.</creatorcontrib><creatorcontrib>Lowe, Mark J.</creatorcontrib><creatorcontrib>Cohen, Jeffrey A.</creatorcontrib><creatorcontrib>Ruggieri, Paul M.</creatorcontrib><creatorcontrib>Ontaneda, Daniel</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of neuroimaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Kunio</au><au>McGinley, Marisa P.</au><au>Jones, Stephen E.</au><au>Lowe, Mark J.</au><au>Cohen, Jeffrey A.</au><au>Ruggieri, Paul M.</au><au>Ontaneda, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis</atitle><jtitle>Journal of neuroimaging</jtitle><addtitle>J Neuroimaging</addtitle><date>2023-01</date><risdate>2023</risdate><volume>33</volume><issue>1</issue><spage>85</spage><epage>93</epage><pages>85-93</pages><issn>1051-2284</issn><eissn>1552-6569</eissn><abstract>Background and Purpose
The clinical correlation of gadolinium‐based contrast agents (GBCAs) has not been well studied in multiple sclerosis (MS). We investigated the extent to which the number of GBCA administrations relates to self‐reported disability and performance measures.
Methods
A cohort of MS patients was analyzed in this retrospective observational study. The main outcome was the association between the cumulative number of GBCA exposures (linear or macrocyclic GBCA), Patient‐Determined Disease Steps (PDDS), and measures of physical and cognitive performance (walking speed test, manual dexterity test [MDT], and processing speed test [PST]). The analysis was performed first cross‐sectionally and then longitudinally.
Results
The cross‐sectional data included 1059 MS patients with a mean age of 44.0 years (standard deviation = 11.2). While the contrast ratio in globus pallidus weakly correlated with PDDS, MDT, and PST in a univariate correlational analysis (coefficients, 95% confidence interval [CI] = 0.11 [0.04, 0.18], 0.15 [0.08, 0.21], and –0.16 [–0.10, –0.23], respectively), the associations disappeared after covariate adjustment. A significant association was found between number of linear GBCA administrations and PDDS (coefficient [CI] = –0.131 [–0.196, –0.067]), and MDT associated with macrocyclic GBCA administrations (–0.385 [–0.616, –0.154]), but their signs indicated better outcomes in patients with greater GBCA exposures. The longitudinal data showed no significant detrimental effect of macrocyclic GBCA exposures.
Conclusion
No detrimental effects were observed between GBCA exposure and self‐reported disability and standardized objective measures of physical and cognitive performance. While several weak associations were found, they indicated benefit on these measures.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36181666</pmid><doi>10.1111/jon.13057</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7833-8138</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1051-2284 |
ispartof | Journal of neuroimaging, 2023-01, Vol.33 (1), p.85-93 |
issn | 1051-2284 1552-6569 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9847209 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Adult Clinical Investigative Study Cognitive ability Contrast agents Contrast media Contrast Media - adverse effects Cross-Sectional Studies Exposure Gadolinium Gadolinium - adverse effects Gadolinium DTPA gadolinium‐based contrast agent Globus pallidus Humans magnetic resonance imaging Magnetic Resonance Imaging - methods Manual dexterity Multiple sclerosis Multiple Sclerosis - diagnostic imaging Neuroimaging Organometallic Compounds Original Research Processing Speed Retrospective Studies |
title | Gadolinium‐based contrast agent exposures and physical and cognitive disability in multiple sclerosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A19%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gadolinium%E2%80%90based%20contrast%20agent%20exposures%20and%20physical%20and%20cognitive%20disability%20in%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neuroimaging&rft.au=Nakamura,%20Kunio&rft.date=2023-01&rft.volume=33&rft.issue=1&rft.spage=85&rft.epage=93&rft.pages=85-93&rft.issn=1051-2284&rft.eissn=1552-6569&rft_id=info:doi/10.1111/jon.13057&rft_dat=%3Cproquest_pubme%3E2720430212%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2764723845&rft_id=info:pmid/36181666&rfr_iscdi=true |